A Seamless Phase 2A-B Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of an Investigational New Drug in Patients with Early Alzheimers Disease (AD)

Grants and Contracts Details


Vivoryon Therapeutics [Vivoryon] has developed a novel drug candidate, varoglutamstat (PQ912), for the potential treatment of early AD. Varoglutamstat is a first-in-class, highly specific and potent small molecule with a unique mechanism of action. In preclinical models, these toxic effects can be attenuated with varoglutamstat treatment. This clinical study targets early AD with the goal of improving cognition and everyday function and attenuating longer term disease progression through its dual pathways of varoglutamstat’s mode of action.
Effective start/end date10/1/22 → 2/28/25


  • University of California San Diego Health: $44,714.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.